Sequana Medical NV (EBR:SEQUA)

Market Cap	43.61M
Revenue (ttm)	n/a
Net Income (ttm)	-51.85M
Shares Out	60.40M
EPS (ttm)	-1.11
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	130,409
Average Volume	324,633
Open	0.7160
Previous Close	0.7220
Day's Range	0.7050 - 0.7190
52-Week Range	0.6460 - 4.3900
Beta	-0.09
RSI	32.40
Earnings Date	Dec 15, 2025

About Sequana Medical NV

Sequana Medical NV develops and commercializes treatments for patients with diuretic-resistant fluid overload in liver disease, cancer, and heart failure in Belgium, Germany, France, and internationally. The company offers alfapump system, an implantable pump system for the treatment of refractory liver ascites and malignant ascites; and Direct Sodium Removal (DSR) for the treatment of fluid overload spread across the body. Sequana Medical NV was founded in 2006 and is headquartered in Gent, Belgium.

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2006
• Employees: 48
• Stock Exchange: Euronext Brussels
• Ticker Symbol: SEQUA

Financial Performance

In 2024, Sequana Medical NV's revenue was 105,500, a decrease of -85.19% compared to the previous year's 712,173. Losses were -44.65 million, 37.1% more than in 2023.